[{"orgOrder":0,"company":"Biolojic Design","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapy","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"","sponsorNew":"Biolojic Design \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Eli Lilly"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Aulos","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Biolojic Design \/ Biolojic Design"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Aulos","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Biolojic Design \/ Biolojic Design"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"BD9","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Nektar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"","sponsorNew":"Biolojic Design \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Merck KGaA"}]